NOVN Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 liep. 2023 @ 23:00):

Stats
Šios dienos apimtis	6.93M
Vidutinė apimtis	1.04M
Rinkos kapitalizacija	2.64M
EPS	$0 ( 2024-03-28 )
Kita pelno data	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.112
ATR14	$0.103 (183.93%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-27	Sanders Machelle	Sell	11 553	Common Stock
2023-06-06	John A. Donofrio	Buy	85 000	Restricted Stock Units
2023-06-06	Gay John M.	Buy	200 000	Restricted Stock Units
2023-06-07	Gay John M.	Buy	65 000	Common Stock
2023-06-06	Gay John M.	Buy	65 000	Restricted Stock Units

INSIDER POWER
60.90
Last 97 transactions
Buy: 4 746 863 \| Sell: 340 227

Tūris Koreliacija

Ilgas: -0.41 (neutral)

Trumpas: -0.55 (weak negative)

Signal:(24.752) Neutral

Novan Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Novan Inc Koreliacija - Valiuta/Žaliavos

-0.31
( neutral )

-0.57
( weak negative )

-0.62
( weak negative )

-0.81
( strong negative )

0.56
( weak )

0.32
( neutral )

Novan Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2022
Pajamos:	$23.61M
Bruto pelnas:	$16.23M (68.74 %)
EPS:	$-0.890

FY	2021
Pajamos:	$2.96M
Bruto pelnas:	$0.00 (0.00 %)
EPS:	$-1.740

Financial Reports:

No articles found.

Novan Inc

Novan, Inc., a pre-commercial nitric oxide-based pharmaceutical company, focuses on dermatology and anti-infective therapies. Its clinical stage dermatology drug candidates include SB204, a topical monotherapy for the treatment of acne vulgaris; SB206, a topical anti-viral gel for the treatment of viral skin infections; SB208, a topical broad-spectrum anti-fungal gel for the treatment of fungal infections of the skin and nails, including athlete's foot and fungal nail infections; and SB414, a topical cream-based gel product candidate for the treatment of inflammatory skin diseases. The company also develops SB207, an anti-viral product candidate for the treatment of external genital warts; WH602, a nitric oxide-containing intravaginal gel to treat high-risk human papilloma virus (HPV); WH504, a non-gel formulation product candidate to treat high-risk HPV; and SB019 for the treatment of SARS-CoV-2. Novan, Inc. has a license agreement with Sato Pharmaceutical Co., Ltd.; and a strategic alliance with Orion Corporation. Novan, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.